STOCK TITAN

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)

Coya Therapeutics (NASDAQ: COYA) announced positive results from a Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in Alzheimer's Disease patients. The study met its primary safety endpoints and secondary endpoints for Regulatory T cell enhancement. The trial, involving 38 participants, tested two dosing regimens: every 4 weeks (q4wks) and every 2 weeks (q2wks). The q4wks dosing showed promising results, including cognitive stabilization and improved cerebrospinal fluid biomarkers. Notably, the q4wks group demonstrated a 4.93-point improvement in ADAS-Cog14 scores compared to placebo, and significant improvements in CSF Aβ42 levels. The treatment was well-tolerated with no serious adverse events reported.

Coya Therapeutics (NASDAQ: COYA) ha annunciato risultati positivi da uno studio clinico di Fase 2 sull'interleuchina-2 a basso dosaggio (LD IL-2) in pazienti affetti da Alzheimer. Lo studio ha raggiunto i principali endpoint di sicurezza e gli endpoint secondari per il miglioramento delle cellule T regolatorie. Il trial, che ha coinvolto 38 partecipanti, ha testato due schemi posologici: ogni 4 settimane (q4wks) e ogni 2 settimane (q2wks). La somministrazione q4wks ha mostrato risultati promettenti, tra cui stabilizzazione cognitiva e miglioramento dei biomarcatori del liquido cerebrospinale. In particolare, il gruppo q4wks ha dimostrato un miglioramento di 4,93 punti nei punteggi ADAS-Cog14 rispetto al placebo, e significativi miglioramenti nei livelli di Aβ42 nel CSF. Il trattamento è stato ben tollerato, senza eventi avversi gravi riportati.

Coya Therapeutics (NASDAQ: COYA) anunció resultados positivos de un ensayo clínico de Fase 2 de interleucina-2 a baja dosis (LD IL-2) en pacientes con enfermedad de Alzheimer. El estudio cumplió con los principales objetivos de seguridad y los objetivos secundarios para la mejora de las células T reguladoras. El ensayo, que involucró a 38 participantes, probó dos esquemas de dosificación: cada 4 semanas (q4wks) y cada 2 semanas (q2wks). La dosificación q4wks mostró resultados prometedores, incluyendo estabilización cognitiva y mejora en los biomarcadores del líquido cefalorraquídeo. Notablemente, el grupo q4wks demostró una mejora de 4.93 puntos en las puntuaciones ADAS-Cog14 en comparación con el placebo, y mejoras significativas en los niveles de Aβ42 en el LCR. El tratamiento fue bien tolerado sin eventos adversos graves reportados.

Coya Therapeutics (NASDAQ: COYA)는 알츠하이머 병 환자에 대한 저용량 인터루킨-2(LD IL-2)에 대한 2상 임상 시험에서 긍정적인 결과를 발표했습니다. 이 연구는 주요 안전성 목표와 규제 T 세포 향상을 위한 2차 목표를 달성했습니다. 38명의 참가자가 포함된 이 시험은 4주마다(q4wks)와 2주마다(q2wks) 두 가지 투여 요법을 시험했습니다. q4wks 투여는 인지 안정화 및 뇌척수액 바이오마커 개선을 포함한 유망한 결과를 나타냈습니다. 특히, q4wks 그룹은 위약 대비 ADAS-Cog14 점수가 4.93점 개선되었으며, CSF Aβ42 수준에서 유의미한 개선을 보였습니다. 치료는 잘 견디었으며 심각한 부작용이 보고되지 않았습니다.

Coya Therapeutics (NASDAQ: COYA) a annoncé des résultats positifs d'un essai clinique de Phase 2 sur l'interleukine-2 à faible dose (LD IL-2) chez des patients atteints de la maladie d'Alzheimer. L'étude a atteint ses principaux objectifs de sécurité ainsi que les objectifs secondaires concernant l'amélioration des cellules T régulatrices. L'essai, impliquant 38 participants, a testé deux schémas posologiques : toutes les 4 semaines (q4wks) et toutes les 2 semaines (q2wks). Le traitement q4wks a montré des résultats prometteurs, y compris une stabilisation cognitive et une amélioration des biomarqueurs du liquide céphalo-rachidien. En particulier, le groupe q4wks a démontré une amélioration de 4,93 points des scores ADAS-Cog14 par rapport au placebo, et des améliorations significatives des niveaux d'Aβ42 dans le LCR. Le traitement a été bien toléré, sans événements indésirables graves signalés.

Coya Therapeutics (NASDAQ: COYA) hat positive Ergebnisse aus einer Phase-2-Studie zu niedrigdosierter Interleukin-2 (LD IL-2) bei Alzheimer-Patienten bekannt gegeben. Die Studie erreichte die primären Sicherheitsziele und die sekundären Ziele zur Verbesserung der regulatorischen T-Zellen. Die Studie, an der 38 Teilnehmer beteiligt waren, testete zwei Dosierungsschemata: alle 4 Wochen (q4wks) und alle 2 Wochen (q2wks). Die q4wks-Dosierung zeigte vielversprechende Ergebnisse, darunter kognitive Stabilisierung und verbesserte Biomarker im Liquor cerebrospinalis. Bemerkenswerterweise zeigte die q4wks-Gruppe eine Verbesserung von 4,93 Punkten bei den ADAS-Cog14-Werten im Vergleich zur Placebogruppe und signifikante Verbesserungen der Aβ42-Werte im CSF. Die Behandlung wurde gut vertragen; es wurden keine schwerwiegenden unerwünschten Ereignisse gemeldet.

Positive
  • Met primary safety endpoints with no serious adverse events
  • Successful secondary endpoint showing significant Treg cell population enhancement
  • 4.93-point improvement in ADAS-Cog14 scores vs placebo in q4wks group
  • Significant improvement in CSF Aβ42 levels in q4wks group
  • Stabilization of CSF Neurofilament Light Chain levels in q4wks group
Negative
  • q2wks dosing group showed no benefits in exploratory endpoints
  • Higher dose (q2wks) resulted in reduction of Foxp3 expression, indicating compromised Treg functionality

Insights

The Phase 2 trial results for low-dose IL-2 in Alzheimer's disease demonstrate significant promise. The q4wks dosing regimen showed remarkable outcomes, with a 27% slower decline in CDR-SOB scores versus placebo and a clinically meaningful 4.93-point improvement in ADAS-Cog14 scores. The study revealed important dose-dependent effects, with q4wks dosing proving optimal for maintaining Treg functionality and cognitive benefits.

Key biomarker improvements include significant increases in CSF Aβ42 levels and stabilization of CSF NfL, indicating potential disease-modifying effects. The successful meeting of safety endpoints and targeted biological activity without off-target effects positions this therapy favorably. For COYA, these results validate their platform approach and strengthen the rationale for their combination therapy strategy, particularly COYA 302 for ALS and FTD.

This trial represents a significant advancement in AD therapeutic development, particularly in its novel approach to immune modulation. The stabilization of cognitive decline and improvement in multiple CSF biomarkers with the q4wks regimen is particularly noteworthy. The dose-dependent relationship discovered between IL-2 administration and Treg functionality provides important insights for optimal therapeutic dosing.

The biomarker data is especially compelling - the improvement in CSF Aβ42 levels and stabilization of NfL and GFAP suggest potential disease-modifying effects, rather than just symptomatic relief. This multi-modal evidence of biological activity, combined with cognitive stabilization, positions LD IL-2 as a promising therapeutic candidate in the challenging AD treatment landscape.

  • Study met Primary and Secondary Endpoints for Safety and Regulatory T cell (Treg) Cell Population Enhancement, respectively, with no off-target effects on T effector lymphocytes, providing further evidence of target engagement
  • Exploratory Endpoints demonstrated cognitive stabilization on treatment vs. cognitive declines on placebo for LD IL-2 dosing every 4 weeks (LD IL-2 q4wks), which was associated with significant improvement in cerebrospinal fluid (CSF) soluble Aβ42 levels and stabilized CSF Neurofilament Light Chain (NfL)
  • Study supports and increases confidence in Treg modulation strategies in neurodegenerative conditions and in advancing LD IL-2 q4wks and LD IL-2 q4wks combination strategies (i.e. COYA 302) in AD and other related diseases

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that results from the placebo-controlled Phase 2 clinical trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease were announced today at the 17th Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid, Spain. The study was led by Dr. Alireza Faridar and Dr. Stanley Appel from the Houston Methodist Research Institute. Dr. Appel is a member of Coya’s Scientific Advisory Board. The study received funding from the Alzheimer's Association, the Gates Foundation, and the National Institute on Aging, with additional support from Coya. The presentation summarizing the clinical results is available for viewing here.

“We want to express our gratitude to the investigators for this study. We believe this trial strongly supports and adds further validation of Coya’s approach in modulating Treg function as a platform to address neurodegenerative diseases,” said Arun Swaminathan, Ph.D., incoming CEO of Coya. “These monotherapy treatment results increase our confidence that combinations of COYA 301, our proprietary LD IL-2, with other drug targets have strong potential in treating Alzheimer's Disease. In addition, this data on LD IL-2 alone provides additional confidence in COYA 302, our proprietary combination of LD IL-2 and cytotoxic T lymphocyte-associated antigen 4 immunoglobulin fusion protein (CTLA4-Ig) in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) based on increased and more durable Treg suppressive function observed with the combination in patients with ALS.”

Study Design:

The investigator-initiated, randomized, double-blind, placebo-controlled Phase 2 trial evaluated two dosing regimens of subcutaneous low-dose interleukin-2 in 38 participants with Alzheimer’s disease that were between the ages of 50 to 86 and had Mini-Mental State Examination (MMSE) scores ranging from 12 to 26.

Of the 38 total participants, 22 were randomized in a 1:1 ratio to receive either 5 days of LD IL-2 (106 IU/day) (LD IL-2 q4wks) or placebo every 4 weeks for 21 weeks. An additional 16 participants were randomized in a 2:1 ratio to receive 5-day cycles of LD IL-2 every 2 weeks (LD IL-2 q2wks) or placebo for the same 21-week duration. All participants were monitored for 9 weeks post-treatment, resulting in a total study period of 30 weeks. Demographics and baseline disease characteristics were comparable among the treatment groups.

The primary endpoint was the incidence and severity of adverse events (AEs), with the secondary endpoint evaluating changes in Tregs. Exploratory endpoints assessed changes in cerebrospinal fluid (CSF), AD-related biomarkers, and cognitive status.

Study Results:

The study successfully met its primary and secondary endpoints, demonstrating that treatment with low-dose interleukin-2 is safe and well-tolerated in patients with Alzheimer’s disease. Notably, LD IL-2 showed targeted biological activity, evidenced by a significant expansion of regulatory T cell populations in the LD IL-2 q4wks group without any off-target effects on other peripheral lymphocytes. Additionally, the q4wks regimen led to significant improvements (defined by increased levels) in cerebrospinal fluid (CSF)-soluble Aβ42 levels, an indicator of amyloid pathology, and showed a promising trend in stabilizing cognitive function, with a clinically meaningful 4.93-point improvement1 in the ADAS-Cog14 score compared to placebo.

In contrast, the q2wks group, representing the higher total dose cohort, did not exhibit benefits in exploratory endpoints, underscoring the importance of appropriate IL-2 dosing for maintaining Treg functionality and its associated effects on CSF biomarkers and cognitive outcomes. LD IL-2 q2wks dosing also resulted in a reduction of Foxp3 expression, a critical marker of Treg functionality (a lower level or loss of Foxp3 expression is associated with unstable/dysfunctional Tregs). While these unstable Tregs continue to show suppressive immune response in vitro, they may lose their immunomodulatory functions in vivo, potentially explaining the dose impact on Treg populations and associated exploratory endpoints. As a result of these data, the Company will likely advance LD IL-2 q4wks.

Primary Endpoint (Safety and Tolerability): All patients completed the 21-week treatment phase. The proportion of patients experiencing adverse events (AEs) was similar between the LD IL-2 treatment groups and the placebo group, with no serious AEs or deaths reported. The most common AEs in the LD IL-2 groups included mild erythema at the injection site and a slight increase in eosinophil counts.

Secondary Endpoint (Treg Cell Populations): There was a significant increase (p < 0.05) in the percentage of CD4+ FOXP3+CD25 high Tregs, mean fluorescence intensity (MFI) of Foxp3, Treg CD25 MFI, and Treg suppression of T responders following both dosing regimens of LD IL-2 treatment compared to placebo. Notably, the LD IL-2 q4wks treatment group showed greater enhancement in both Treg numbers and Foxp3 MFI compared to the q2wks group. The loss of Foxp3 expression in the q2wks group (back to baseline levels equivalent to placebo) indicated that higher IL-2 dosing may compromise Treg functionality. Repeated stimulation of Tregs without sufficient rest periods has been reported to result in exhausted and unstable Treg populations2. Published studies also suggest an inverse relationship between IL-2 dose and Treg functionality3,4.

  1. For patients with mild AD, a change of +3 on the ADAS-Cog has been described as clinically meaningful to assess worsening (Muir et al., Alzheimer’s Dement 2024; 20:3352–3363).
  2. Hoffmann, et al. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol 2009; 39 (4): 1088-1097.
  3. Gao et al., Dynamically modeling the effective range of IL-2 dosage in the treatment of systemic lupus erythematosus. iScience 2022; 25: 104911
  4. Moon B-I., et al., Functional Modulation of Regulatory T Cells by IL-2. PLoS ONE 2015; 10(11)

Exploratory Endpoint (Cognitive Function & Cerebrospinal Fluid (CSF) Biomarkers):

Although not powered for significance, the analyses of exploratory endpoints also showed encouraging results.

Cognitive Function: The Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog14) scores on day 148 showed a slight improvement following LD IL-2 q4wks administration (change from baseline: -0.450), vs. placebo, which worsened 4.480 from baseline, demonstrating a clinically meaningful difference of 4.93 points (P=0.061). This cognitive effect was not observed in the LD IL-2 q2wks administration, which demonstrated a similar decline as placebo.

Stabilization of ADCS-CGIC (Alzheimer's Disease Assessment Scale – Cognitive Subscale) scores was observed in both the IL-2 q4wks and IL-2 q2wks groups on day 148 compared to the placebo arm, which declined from baseline.

The change from baseline in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) on Day 148 was 1.401 in the LD IL-2 q4wks group, 1.976 in the LD IL-2 q2wks group, and 1.893 in the placebo group, suggesting a 27% slower decline in CDR-SOB scores following LD IL-2 q4wks treatment compared to the placebo group. These findings suggest that LD IL-2 q4wks may be an optimal dose for cognitive effects in mild to moderate AD, which was the dose associated with a robust and sustained increase in Treg populations along with enhanced expression of the IL-2 receptor, CD25, and the Treg transcription factor, FoxP3. Furthermore, the cognitive effect of this dose was associated with significant improvements in AD pathology in the CSF and stabilization of CSF inflammatory markers.

CSF Aβ42: Low CSF Aβ42 is universally associated with AD, and higher CSF Aβ42 levels are independently associated with slowing cognitive impairment and clinical decline. Increases in Aβ42 may represent a mechanism of potential benefit of intervention. LD IL-2 q4wks treatment significantly improved CSF Aβ42 levels after the 21-week treatment, compared to the placebo group (p = 0.045). LD IL-2 q2wks treatment did not significantly modify CSF Aβ42 levels. These data further suggest the dose-dependent effect of LD IL-2 on Treg cell populations (i.e. FOXP3) is associated with effects on CSF Aβ42.

CSF Neurofilament Light Chain (NfL): NfL is increasingly recognized as a promising biomarker for neurodegeneration (neuronal/axonal degeneration) in AD. Residing predominantly within myelinated axons, NfL is a cytoskeletal protein that plays a role in maintaining neuronal structural integrity and axonal caliber. Neuronal damage in neurodegenerative diseases releases NfL into the extracellular space and eventually into the CSF, resulting in higher CSF NfL levels in AD.

CSF NfL levels remained stable following LD IL-2 q4wks administration and almost reached statistical significance vs. placebo (which increased by 217.3pg/mL) (p=0.060). CSF NfL increased by 148.0 pg/mL in the LD IL-2 q2wks arm. These data suggest the dose-dependent effect of LD IL-2 on Treg cell populations (i.e. FOXP3) is associated with effects on CSF NfL.

CSF Glial Fibrillary Acidic Protein (GFAP): GFAP is an astrocytic cytoskeleton intermediate filament protein. GFAP is a marker of astrogliosis, which is the abnormal activation and proliferation of astrocytes. Astrogliosis is associated with Aβ plaques in the prodromal stages of AD.

CSF GFAP levels showed a slight improvement following LD IL-2 q4wks administration (change from baseline: -214.1 pg/mL) and remained almost stable in the LD IL-2 q2wks group (change from baseline: 17.4 pg/mL), but increased by 1548.99 pg/mL in the placebo group.

About Alzheimer’s Disease

Alzheimer's disease is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer's disease accounts for up to 80% of dementia cases, affecting an estimated 5.7 million Americans. In more than 90% of people with Alzheimer’s, symptoms do not appear until after age 60. The incidence of the disease increases with age and doubles every 5 years beyond age 65. Alzheimer's is a progressive disease, where dementia symptoms gradually worsen over a number of years. In its early stages, memory loss is mild, but with late-stage Alzheimer's, individuals lose the ability to carry on a conversation and respond to their environment. It is the sixth leading cause of death among all adults and the fifth leading cause for those aged 65 or older. On average, a person with Alzheimer's lives 4 to 8 years after diagnosis but can live as long as 20 years, depending on other factors.1,2

  1. Alzheimer’s Association (www.alz.org)
  2. Centers for Disease Control and Prevention (www.cdc.gov)

About COYA 301

COYA 301 is the company’s proprietary investigational low-dose interleukin-2 (IL-2) intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and is designed for subcutaneous administration. COYA 301 is an investigational product not yet approved by the FDA or any other regulatory agency.

About COYA 302

COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. COYA 302 is comprised of proprietary low dose interleukin-2 (LD IL-2) and cytotoxic T lymphocyte-associated antigen 4 immunoglobulin fusion protein (CTLA-4 Ig) and is being developed for subcutaneous administration for the treatment of patients with ALS, FTD, and Parkinson’s Diseases (PD). These mechanisms may have additive or synergistic effects.

In February of 2023, Coya announced results from a proof-of-concept, open-label clinical study evaluating commercially available LD IL-2 and CTLA-4 Ig in a small cohort of patients with ALS conducted at the Houston Methodist Research Institute (Houston, Texas) by Stanley Appel, M.D., Jason Thonhoff, M.D., Ph.D., and David Beers, Ph.D. This study was the first-of-its-kind to evaluate this dual-mechanism immunotherapy for the treatment of ALS. Patients in the study received investigational treatment for 48 consecutive weeks and were evaluated for safety and tolerability, Treg function, serum biomarkers of oxidative stress and inflammation, and clinical functioning as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) scale.

During the 48-week treatment period, the therapy was well tolerated. The most common adverse event was mild injection-site reactions. No patient discontinued the study, and no deaths or other serious adverse events were reported.

Patients' disease progression was measured using the ALSFRS-R scale, a validated rating tool for monitoring the progression of disability in patients with ALS. The mean (±SD) ALSFRS-R scores at week 24 (33.75 ±3.3) and week 48 (32 ±7.8) after initiation of treatment were not statistically different compared to the ALSFRS-R score at baseline (33.5 ±5.9), suggesting significant amelioration in the progression of the disease over the 48-week treatment period.

Treg suppressive function, expressed as a percentage of inhibition of proinflammatory T cell proliferation, showed a statistically significant increase over the course of the treatment period and was significantly reduced at the end of the 8-week washout post-treatment period. Treg suppressive function at 24 weeks (79.9 ±9.6) and 48 weeks (89.5 ±4.1) were significantly higher compared to baseline (62.1 ±8.1) (p<0.01), suggesting enhanced and durable Treg suppressive function over the course of treatment. In contrast, Treg suppressive function (mean ±SD) was significantly decreased at the end of the 8-week washout period compared to end-of-treatment at week 48 (70.3 ±8.1 vs. 89.5 ±4.1, p <0.05).

The study also evaluated serum biomarkers of inflammation, oxidative stress, and lipid peroxides. The available data up to 16 weeks after initiation of treatment suggest a decrease in these biomarker levels, which is consistent with the observed enhancement of Treg function. The evaluation of the full biomarker data is ongoing.

COYA 302 is an investigational product not yet approved by the FDA or any other regulatory agency.

About Coya Therapeutics, Inc.

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in a lack of homeostasis of the immune system.

Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

COYA 302 – the Company’s lead biologic investigational product or “Pipeline in a Product”– is a proprietary combination of COYA 301 (Coya’s proprietary LD IL-2) and CTLA4-Ig for subcutaneous administration with a unique dual mechanism of action that is now being developed for the treatment of Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinson’s Disease, and Alzheimer’s Disease. Its multi-targeted approach enhances the number and anti-inflammatory function of Tregs and simultaneously lowers the expression of activated microglia and the secretion of pro-inflammatory mediators. This synergistic mechanism may lead to the re-establishment of immune balance and amelioration of inflammation in a sustained and durable manner that may not be achieved by either low-dose IL-2 or CTLA4-Ig alone.

For more information about Coya, please visit www.coyatherapeutics.com

Forward-Looking Statements

This press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements.

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; ; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investors

David Snyder, CFO

david@coyatherapeutics.com

CORE IR

Bret Shapiro

brets@coreir.com

561-479-8566

Media

For Coya Therapeutics:

Kati Waldenburg

media@coyatherapeutics.com

212-655-0924

Source: Coya Therapeutics, Inc.

FAQ

What were the main results of COYA's Phase 2 Alzheimer's trial?

The trial met both primary safety endpoints and secondary endpoints for Treg enhancement, with the q4wks dosing showing cognitive stabilization and improved CSF biomarkers.

How many patients participated in COYA's Alzheimer's study?

The study included 38 participants with mild to moderate Alzheimer's Disease, aged 50-86 years.

What was the difference in ADAS-Cog14 scores between treatment and placebo in COYA's trial?

The q4wks treatment group showed a 4.93-point improvement in ADAS-Cog14 scores compared to placebo.

Were there any serious adverse events in COYA's LD IL-2 trial?

No serious adverse events were reported, with only mild injection site reactions and slight increases in eosinophil counts noted.

Coya Therapeutics, Inc.

NASDAQ:COYA

COYA Rankings

COYA Latest News

COYA Stock Data

102.25M
15.04M
7.03%
19.97%
1.18%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HOUSTON